A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.
Gary Edward RichardsonRaed Al-RajabiDipesh UpretyAnis HamidStephen K WilliamsonJoaquina Celebre BarandaHirva MamdaniYa-Li LeeNitika NitikaLi LiXingli WangXunwei DongPublished in: Cancers (2023)
FN-1501 demonstrated reasonable safety, tolerability, and preliminary activity against solid tumors in doses up to 170 mg. Dose escalation was terminated based on 2 DLTs occurring at the 226 mg dose level.